
Home » Jennerex enrolls first patient in phase IIb liver cancer trial
Jennerex enrolls first patient in phase IIb liver cancer trial
November 4, 2011
Jennerex has initiated enrollment and the first patient has
been randomized in a phase IIb clinical trial called TRAVERSE. The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC. In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.
been randomized in a phase IIb clinical trial called TRAVERSE. The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC. In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.
The TRAVERSE phase IIb clinical trial is designed to enroll 120 patients
with advanced liver cancer who have failed sorafenib therapy. The
randomized study will be conducted at approximately 45 sites worldwide
including North America, South Korea, Taiwan, Hong Kong, and Europe. The
primary objective of the trial is to determine the overall survival
benefit for patients receiving JX-594 with best supportive care, compared
to best supportive care alone in patients with refractory advanced liver
cancer.
Upcoming Events
-
05Dec
-
14Apr